Compare FRAF & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRAF | ALLO |
|---|---|---|
| Founded | 1906 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.2M | 252.9M |
| IPO Year | N/A | 2018 |
| Metric | FRAF | ALLO |
|---|---|---|
| Price | $49.78 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.27 |
| AVG Volume (30 Days) | 59.0K | ★ 6.4M |
| Earning Date | 01-27-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | ★ 88.84 | N/A |
| EPS | ★ 4.74 | N/A |
| Revenue | ★ $85,923,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.47 | ★ N/A |
| Revenue Growth | ★ 24.15 | N/A |
| 52 Week Low | $32.39 | $0.86 |
| 52 Week High | $59.95 | $3.78 |
| Indicator | FRAF | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 50.95 |
| Support Level | $48.32 | $1.56 |
| Resistance Level | $50.25 | $1.84 |
| Average True Range (ATR) | 1.93 | 0.15 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 48.71 | 36.89 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.